- Home
- » Tags
- » Dostarlimab
Top View
- Endometrial Cancer Molecular Characterization: the Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
- Tashanna K. Myers, MD, FACOG, FACS
- Medi-Cal Rx Contract Drugs List
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
- CHMP Agenda of the 20-23 July 2020 Meeting
- The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
- FDA Approves 100Th Monoclonal Antibody Product
- Oncology Injectable and Infused Medications
- Specialty Injectables Prior Authorization List
- Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
- Minutes of the CHMP Meeting 20-23 July 2020
- Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
- Regeneron Pharmaceuticals, Inc
- Fc-Engineering for Modulated Effector Functions—Improving Antibodies
- Oncology Medications Policy (1403)
- Safety and Efficacy of the Anti–PD-1 Monoclonal Antibody Dostarlimab in Patients with Recurrent Or Advanced Dmmr Endometrial Cancer
- THERAPY CODES 4-Factor Concentrate F014 5A2A F017
- SUMMARY of DRUG LIMITATIONS Medications Listed in This Document May Or May Not Require a Prior Authorization
- CHMP Agenda of the 25-29 January 2021 Meeting
- Highlights from ASCO-GI 2021 from EORTC Gastrointestinal Tract Cancer Group ✉ Thibaud Koessler 1,2,3 , Maria Alsina3,4, Dirk Arnold3,5, Irit Ben-Aharon3,6, Manfred P
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Mandatory Specialty Drug List
- Prior Authorization and Investigational Services List
- Pharmacogenetic/Pharmacogenomic Testing And
- (2006.01) C07d 413/14
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- PDF of Antibody News
- Services That Require Precertification Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services
- List Item Applications for New Human
- PDF of Antibody News
- Novel Discoveries in Endometrial Cancer: Are We Finally Making Progress? Moderators: Melissa Geller, MD, and Shannon Westin, MD
- Swissmedic Journal 01 2021
- Winter 2021 Pharmacy Market Outlook 2 Table of Contents
- Labeling: • Immune-Mediated Adverse Reactions [See Warnings and Precautions (5.1)] • Infusion-Related Reactions [See Warnings and Precautions (5.2)]
- Keytruda® (Pembrolizumab)
- Contract Drugs List Part 1 – Prescription Drugs (A Through D) Page Updated: November 2020
- JEMPERLI (Dostarlimab-Gxly) Injection, for Intravenous Use Immune-Mediated Nephritis with Renal Dysfunction, Immune-Mediated Initial U.S
- ATC/DDD Classification (Temporary)
- Treating Endometrial Cancer If You've Been Diagnosed with Endometrial Cancer, Your Cancer Care Team Will Discuss Your Treatment Options with You
- Rxoutlook® 1St Quarter 2021
- Clinical Trials Summary Our R&D Pipeline 20 Vaccines and 42 Medicines in 77 Different Programs
- Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Eligibility Criteria Conditions &
- New Developments in Uterine Cancer Matthew A
- Dostarlimab (Jemperli®) for the Treatment of Patients with Recurrent Or Advanced Mismatch Repair Deficient (Dmmr)/Microsatelli
- JEMPERLI 500 Mg Concentrate for Solution for Infusion
- Specialty Pipeline MONTHLY UPDATE
- Publication Agenda CHMP 07-10 December 2020
- Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- Medication Administration Site of Care
- PHYSICIAN ADMINISTERED DRUG PROGRAM (PADP) FEE SCHEDULE EFFECTIVE JANUARY 1, 2021 the Inclusion of a Rate on This Table Does Not Guarantee That a Service Is Covered
- Generic Pipeline Forecast This Section Provides a Summary of Upcoming First-Time Generic Drugs and Biosimilars That May Be Approved in the Upcoming Two Years